Bluetongue disease causes high morbidity and can cause up to 75% mortality in domestic livestock (5) . Bluetongue virus (BTV), the etiological agent of the disease, is transmitted between hosts by several species of biting midges of the Culicoides genus, which determine its geographic range (27) . The virus has a global distribution and is endemic in many tropical and subtropical regions including the United States, Central America, parts of South America, Africa, Southeast Asia, and northern Australia, with a more recent emergence into Europe (5, 8, 14-16, 22, 25, 31, 39, 40 ; also press release from the World Organisation for Animal Health, Paris, France, 25 August 2006, http://www.oie.int/eng/press/en_060823.htm).
BTV belongs to the Orbivirus genus of the Reoviridae family and has a segmented genome consisting of 10 linear double-stranded RNA (dsRNA) molecules (33, 36) . The genome segments are classified from segment 1 to segment 10 in decreasing order of size. The virus particle has a layered structure, the outer layer of which is lost before the remaining core particle enters the cytoplasm of the host cell (13, 34, 35) . While the viral genomic dsRNAs never leave the core particle, the core particle itself is transcriptionally active, synthesizing and extruding multiple capped singlestranded mRNA copies of each viral genome segment into the host cell cytoplasm (13, 34, 35) . These transcripts have the dual roles of encoding the viral proteins and serving as templates for the synthesis of the new viral dsRNA genome segments present in progeny virus particles. We have recently shown that the transfection of in vitro synthesized viral mRNAs from core particles into permissive cells is sufficient to initiate an infection (1) .
The introduction of defined mutations into the genomes of many viruses has enabled rational approaches to the molecular dissection of viral gene products and noncoding sequences. Among RNA viruses, initially viruses with a positive-sense genome were recovered from plasmid DNA, such as bacteriophage Q␤ and poliovirus (23, 32) . Later, viruses with negative-sense genomes such as measles virus, influenza virus, and bunyaviruses were recovered entirely from cDNA clones (2, 18, 19, 24) . In recent years the introduction of plasmid-derived sequence into the dsRNA genomes of the Reoviridae has become possible for the Orthoreovirus genus and, to a limited extent, for the Rotavirus genus (9, 10, 26) . Here, we report the first manipulation of a member of the Orbivirus genus (BTV) at the sequence level, using a new approach among dsRNA virus reverse genetics systems based entirely on in vitro synthesized RNA transcripts. The approach taken extends the discovery that BTV transcripts are infectious on transfection of permissive cells (1) by the addition of one or more plasmid-derived T7 transcripts. The reassortment method described is applicable to any genome segment of BTV and requires the construction of a single clone or PCR product for each genome segment being recovered. We report the introduction of a marker sequence into the genome of BTV and the simultaneous replacement of the serotype-specific protein VP2 and the entry protein VP5 with proteins from a different serotype. Furthermore, the recovery of BTV entirely from plasmid-derived T7 transcripts was investigated and found to be viable means of generating BTV with a fully defined genome. This method permits the recovery of mutants in a consistent genetic background with no screening required to remove wild-type virus. were cultured in Dulbecco's modified Eagle's medium supplemented with 5% (vol/vol) fetal bovine serum (FBS) at 35°C in 5% CO 2 . BTV stocks were generated by infecting BSR cells at a multiplicity of infection of 0.1 and harvesting the medium at 3 to 4 days postinfection. Viral stocks were stored at 4°C.
MATERIALS AND METHODS

Cell lines and virus. BSR cells (a clone of
Purification of BTV core particles. BSR cultures were infected with BTV at a multiplicity of infection of 0.02 to 0.1. Transcriptionally active BTV-1 core particles were purified as previously described and stored at 4°C (1) .
Synthesis and purification of BTV mRNA in vitro. BTV core particles were incubated at 40 g/ml at 30°C for 5 to 6 h in BTV core transcription buffer (100 mM Tris-HCl, pH 8.0, 4 mM ATP, 2 mM GTP, 2 mM CTP, 2 mM UTP, 500 M S-adenosylmethionine, 6 mM dithiothreitol, 9 mM MgCl 2 , 0.5U/l RNasin Plus [Promega]). BTV core-derived mRNAs were purified using a previously described method and stored at Ϫ80°C (1).
Reverse transcription-PCR (RT-PCR) amplification of BTV-1 genome segments. cDNA copies of each BTV type 1 (BTV-1) genome segment were amplified from viral dsRNA in a sequence-independent manner using the method of full-length amplification of cDNAs (FLAC) (12) . Briefly, the hairpin anchor primer was ligated to viral dsRNA as described previously, followed by cDNA synthesis from gel-purified genome segments with SuperScript III (Invitrogen) at a concentration of 10 U/l and 55°C for 1 h. PCR amplification was performed using 5Ј phosphorylated FLAC 2 primer (5ЈGAGTTAATTAAGCGGCCGCAG TTTAGAATCCTCAGAGGTC3Ј) with KOD Hot Start DNA Polymerase (Novagen). PacI and NotI sites are in bold type.
T7 plasmid clones used for the synthesis of BTV transcripts. cDNA plasmid clones were constructed for BTV-10 genome segment 10 (pNS3BsmBI), segment 5 (pVP5BsmBI), and segment 2 (pVP2BsmBI), and for all 10 segments of the BTV-1 genome. A mutant version of the BTV-10 segment 10 clone containing an introduced HaeII site (pNS3Hae) and a mutant version of the BTV-1 segment 8 clone containing an introduced BglII site (pBTV1S8Bgl) were also constructed. The functional cassette in each plasmid clone contained a T7 promoter and a BsmBI, BsaI, or BpiI site, with the BTV genome segment located between these elements. The BTV genome segment in each clone was positioned relative to the other two sequence elements such that the T7 transcript derived from plasmid digested with BsmBI, BsaI, or BpiI was predicted to have exactly the same sequence as the mRNA strand of the corresponding BTV genome segment ( Fig. 2A) .
Synthesis of BTV transcripts from cDNA plasmid clones. T7 plasmid clones were digested with BsmBI, BsaI, or BpiI and then extracted once with phenolchloroform and once with chloroform. Each digested plasmid was precipitated with isopropanol in the presence of 0.15 M sodium acetate. DNA pellets were washed twice in 70% (vol/vol) ethanol and dissolved at 1 g/l in 10 mM Tris-HCl, pH 8.0. Transcripts with a 5Ј cap analogue were generated from the digested T7 plasmid clones using a mMESSAGE mMACHINE T7 Ultra Kit (Ambion), using a 4:1 ratio of anti-reverse cap analogue to rGTP. T7 BTV transcripts were extracted once with phenol-chloroform, followed by one extraction with chloroform. Unincorporated ribonucleoside triphosphates were removed by size fractionation using Microspin G-25 columns (GE Healthcare) according to the manufacturer's instructions. The T7 BTV transcripts were precipitated with an equal volume of isopropanol in the presence of 0.15 M sodium acetate. RNA pellets were washed twice in 70% (vol/vol) ethanol, dissolved in sterile diethylpyrocarbonate-treated water, and stored at Ϫ80°C.
Denaturing agarose gel electrophoresis. Purified BTV single-stranded RNA (ssRNA) was analyzed by electrophoresis on 1% agarose in morpholinepropanesulfonic acid electrophoresis buffer in the presence of formaldehyde using standard techniques (29) .
Transfection of cultured cells to recover BTV with one or two cDNA-derived genome segments. BTV mRNAs derived from transcribing cores were mixed with one or more T7 BTV transcripts in Opti-MEM I in the presence of 0.1 U/l RNasin Plus (Promega). The RNA mixture was incubated at 20°C for 30 min before being mixed with Lipofectamine 2000 reagent (Invitrogen) (see below). Confluent BSR monolayers in six-well plates were transfected with 1.5 g of BTV mRNA mixed with 0.75 g of each T7 BTV transcript using Lipofectamine 2000 reagent according to the manufacturer's instructions. At 4 h posttransfection the culture medium was replaced with a 6-ml overlay consisting of minimal essential medium, 2% FBS, and 1.5% (wt/vol) agarose type VII (Sigma). Assays were incubated at 35°C in 5% CO 2 for 72 to 96 h to allow plaques to appear.
Transfection of cultured cells to recover BTV entirely from cDNA-derived genome segments. A total of 300 to 400 ng of each T7 BTV transcript was mixed as described above to produce a complete genome set of T7 BTV transcripts. Transfection of BSR monolayers was performed as described above.
Preparation of dsRNA from transfection-derived BTV plaques. Each plaque was picked into 500 l of Dulbecco's modified Eagle's medium-5% FBS, and 200 l was used to infect 1.5 ϫ 10 6 BSR cells. Infected cells were incubated at 35°C in 5% CO 2 for 72 to 96 h to allow amplification of the BTV. Viral dsRNA was purified from infected BSR cells as previously described (1) .
Screening transfection-derived BTV plaques for reassortants containing the introduced genome segments. Where the genome segment being introduced migrated at a different rate on polyacrylamide gels, screening was done by electrophoresis of the dsRNA on 9% polyacrylamide gels in Tris-glycine buffer (pH 8.3). Gels were poststained for 30 min with ethidium bromide. Where screening was not possible on the basis of the migration rate, RT-PCR followed by restriction endonuclease digestion was used to discriminate between reassortants and wild-type BTV. cDNA was synthesized from 100 ng of heat-denatured viral dsRNA with SuperScript III (Invitrogen), using forward and reverse primers flanking the target region, at 55°C for 1 h. The target region was PCR amplified using Taq DNA polymerase with the same forward and reverse primers and digested with restriction endonucleases. Products were resolved by electrophoresis in agarose gels containing ethidium bromide in Tris-borate-EDTA buffer. Sequence analysis of RT-PCR products was done using dye terminators on ABI 3730XL sequencing machines using the Value Read service of MWG Biotech (30) .
Construction of pNS3Hae and pBTV1S8Bgl. pNS3BsmBI was altered to contain an additional HaeII site by site-directed mutagenesis using primers S10_mt_Hae_409F and S10_mt_Hae_409R by the method of Weiner et al. (37) . Similarly the wild-type BTV-1 S8 clone was altered to introduce a BglII site using primers 5ЈBTV1_S8_BglII and 3ЈBTV1_S8_BglII. Clones were screened for the presence of the introduced site by HaeII or BglII digestion, and the expression cassette was sequenced to identify clones containing no adventitious mutations using the Value Read service of MWG Biotech.
Primers. Mutagenic primers used to generate pNS3Hae from pNS3BsmBI were the following: S10_mt_Hae_409F (5ЈCTACTAGTGGCTGCTGTGGT AGCGCTGCTGACATCAGTTTG3Ј) and S10_mt_Hae_409R (5ЈCAAACT GATGTCAGCAGCGCTACCACAGCAGCCACTAGTAG3Ј). Mutagenic primers used to generate pBTV1S8Bgl from the wild-type BTV-1 S8 clone were 5ЈBTV1_S8_BglII (5ЈGATTTACCAGGTGTGATGAGATCTAACTACGATG TTCGTGAAC3Ј) and 3ЈBTV1_S8_BglII (5ЈCGAACATCGTAGTTAGATCTC ATCACACCTGGTAAATCGGGC3Ј). The mutagenic bases are underlined, and the restriction sites are in bold type.
Primers for the RT-PCR amplification and sequencing of BTV-10 segment 10 were the following: BTV10_S10_238F (5Ј-GGAGAAGGCTGCATTCGCA TCG-3Ј), BTV10_S10_654R (5Ј-CTCATCCTCACTGCGTCATTATATGATTGT TTTTTCATCACTTC-3Ј), BTV10_S10_259F (5Ј-GGAGAAGGCTGCATTCGC ATCG-3Ј), and BTV10_S10_611R (5Ј-CTCATCCTCACTGCGTCATTATATGA TTGTTTTTTCATCACTTC-3Ј).
Primers for RT-PCR amplification from BTV-10 segment 5 were BTV10_ M5_724F (5Ј-ATGACAGCAGACGTGCTAGAGGCGGCATC-3Ј) and BTV10_M5_1590R (5Ј-GCGTTCAAGCATTTCGTAAGAAGAG-3Ј).
Primers for RT-PCR amplification from BTV-10 segment 2 were BTV10_ L2_727F (5Ј-CCGTACGAACGATTTATATCCAGC-3Ј) and BTV10_L2_ 1523R (5Ј-TACTAATTCAGAACGCGCGCC-3Ј).
Primers for RT-PCR amplification of BTV-1 segment 8 were NS2_Bam_T7_F (5Ј-CGGGATCCTAATACGACTCACTATAGTTAAAAAATCCTTGAGT CA-3Ј) and NS2_Bam_R (5Ј-CATGGGATCCGGACCGTCTCCGTAAGTGT AAAATCCCC-3Ј). The primer used for sequencing BTV-1 segment 8 was BTV1_S8_627R (5ЈCAGCTTCTCCAATCTGCTGG3Ј).
RESULTS
Reassortment of genome segments by cotransfection with BTV mRNA from two serotypes. The recovery of infectious BTV from core-derived transcripts through the transfection of permissive cells has been demonstrated (1) . With the aim of producing a reverse genetics system for BTV, the introduction of genome segments from one BTV serotype into another was investigated as an intermediate step prior to the introduction of cDNA-derived genome segments. Infectious core-derived transcripts were prepared from BTV-1 and BTV-9 as previously described (1). The transcripts from the two serotypes were either generated simultaneously in the same transcription reaction or prepared separately and then mixed. Confluent BSR monolayers were transfected with the transcript mixtures, and virus was amplified from the resulting plaques. The dsRNA was purified from each amplified plaque, and the origin of genome segments was determined by electrophoresis on nondenaturing polyacrylamide gels, which allow the discrimination of some genome segments from different isolates. When cosynthesized transcripts from BTV-1 and BTV-9 were used, progeny viruses were generated that had genome segments from both parental sources of transcripts (reassortants). In Fig.  1A , lane 1 contains a reassortant which has segment 1 and segment 4 of BTV-1 in a genetic background of segments which migrate as BTV-9. Similarly, lane 2 contains a reassortant with the segment 3 of BTV-9 in a BTV-1 genetic background, and lane 3 contains a reassortant with segment 1 of BTV-9 in a BTV-1 genetic background. When BTV-1 and BTV-9 transcripts were prepared separately and mixed prior to transfection, reassortant progeny viruses were also generated, indicating that cosynthesis of transcripts is not necessary for reassortment to occur (Fig. 1B) . The frequency at which reassortant progeny were generated was approximately 7 to 10% for both types of transcripts used. These data demonstrated that cotransfection with a mixture of viral transcripts is a viable strategy for the introduction of genome segments from a separate source into the BTV genome.
The introduction of a BTV segment derived from a cDNA clone into the BTV-1 genome. The targeted replacement of a genome segment with a T7 transcript derived from a cDNA clone was subsequently investigated as a model for the introduction of cloned sequences into the BTV genome. The introduction of the BTV-10 segment 10 T7 transcript into the genome of BTV-1 was chosen to allow the rapid screening of plaques based on the fast migration rate of segment 10 of BTV-10 compared to BTV-1 on polyacrylamide gels. The BTV-10 segment 10 T7 transcript was produced from pNS3BsmBI, which has a T7 promoter to generate the correct 5Ј end sequence and a BsmBI site to generate the correct 3Ј end sequence ( Fig. 2A) . BTV-1 transcripts produced from transcribing core particles were mixed with the BTV-10 segment 10 T7 transcript and used to transfect confluent BSR monolayers. A 5:1 molar ratio of T7 transcript to the corresponding core-derived mRNA was found to be best and was used in all experiments. Increasing the ratio of T7 transcript to BTV-1 transcripts reduced the total number of plaques recovered (data not shown). Typically ϳ50 plaques were recovered from each well following the transfection of a six-well dish with 1.5 g of core-derived transcripts plus 0.75 g of T7 transcript. Virus was amplified from these plaques, and the dsRNA was purified. The origin of genome segment 10 was initially determined by electrophoresis of the dsRNA on polyacrylamide gels. dsRNA genome profiles containing the faster migrating segment 10 from BTV-10 were obtained with a sufficiently high frequency (15 to 80%) to make screening of plaques a viable option (Fig. 2B) . The identity of segment 10 was confirmed using RT-PCR, followed by sequencing of a region showing variation between type 1 and type 10 ( Fig. 2C, D , and E). These data demonstrated the recovery of the plasmid-derived BTV-10 segment 10 into the genome of viable BTV-1.
BTV naturally produces reassorted progeny genomes when a cell is infected with two different strains (7) . To exclude the possibility that natural reassortment between two viruses was the origin of the segment 10 reassortants, a BTV-10 segment 10 clone containing an introduced silent HaeII site (pNS3Hae) as a marker was made by the site-directed mutagenesis of pNS3BsmBI. BSR monolayers were transfected with a mixture of BTV-1 core-derived mRNAs and the BTV-10 segment 10 T7 transcript containing the introduced mutation, derived from pNS3Hae. The recovery of virus containing this mutant BTV-10 segment 10 sequence was initially screened for by its increased migration rate on polyacrylamide gels (Fig. 3A) . The introduction of the HaeII site into segment 10 of the BTV genome was confirmed by RT-PCR of dsRNA from plaquepurified virus followed by HaeII digestion (Fig. 3B ) and by sequencing of the RT-PCR product ( Fig. 3C and D) . By sequencing a full-length RT-PCR product, segment 10 was determined to be the same as the segment encoded in pNS3Hae throughout its length (data not shown).
The simultaneous introduction of two BTV-10 segments derived from cDNA clones into the BTV-1 genome. To assess the possibility of simultaneously altering two genome segments, the introduction of the outer capsid protein encoding segments (segments 2 and 5) from BTV-10 into a background of BTV-1 genome segments was investigated. Replacement of these ge- nome segments with the segments from another serotype would enable the serotype of the virus to be altered. T7 transcripts derived from segments 2 and 5 of BTV-10 were prepared from pVP2BsmBI and pVP5BsmBI, respectively, and mixed with BTV-1 core-derived mRNAs at a 5:1 ratio of each T7 transcript to the corresponding core-derived transcript. Confluent BSR cell monolayers were transfected with the RNA mixture, and dsRNA was prepared from the recovered plaques. The origins of segments 2 and 5 were initially assessed by their migration rate on polyacrylamide gels (Fig. 4A ). Both segments 2 and 5 from BTV-10 were recovered together at high frequency (20 to 80%). The change of serotype from serotype 1 to serotype 10 was confirmed by a plaque size reduction assay using anti-BTV-10 rabbit serum (data not shown). Further, the identity of the segments was confirmed by RT-PCR followed by restriction digestion (Fig. 4B and C) . The complete sequences of segment 2 and segment 5 were determined to be those of BTV-10 by RT-PCR amplification and sequencing (data not shown). No progeny (0 out of 19 plaques from three independent experiments) were recovered that contained only segment 2 or only segment 5 from BTV-10, suggesting that viruses containing segment 2 from one parent and segment 5 from the other parent are either of reduced viability or are generated at a lower frequency than the double reassortants. This phenomenon was further supported when the introduction of segment 2 or segment 5 from BTV-10 into BTV-1 was attempted singly, and no reassortant progeny were recovered (data not shown).
The recovery of BTV entirely from T7 transcripts. While the above method is a viable reverse genetics system that allows the manipulation of BTV genome segments, the requirement to screen for reassortant plaques among wild-type plaques could hinder the recovery of slow-growing mutants. The ideal reverse genetics system would permit the assembly of infectious virus entirely from T7 transcripts. To maximize the probability of having a viable clone for every genome segment, RT-PCR amplification of each genome segment was performed with dsRNA of BTV-1 using the sequence-independent FLAC method developed for dsRNA templates (12) . Each RT-PCR product was cloned into pUC19 (38) , and the complete sequence of each clone was compared with the complete sequence of each RT-PCR product in order to determine whether a representative molecule had been cloned in each case (data not shown). Alternative clones were sequenced when coding changes or any differences within 200 nucleotides of the ends of the cloned genome segment were present. Once a complete set of 10 clones was obtained, each genome segment was PCR amplified using the high-fidelity KOD Hot Start DNA Polymerase (Novagen) to introduce a T7 promoter directly upstream of the genome segment and a restriction enzyme site directly downstream ( Fig. 2A) . These functional cassettes were also cloned in pUC19. T7 transcripts synthesized using the restriction-digested plasmid clones were determined to be of the expected size when resolved on 1% denaturing agarose gels (Fig. 5) . T7 transcripts made from restriction-digested plasmids were mixed in equal amounts of 0.3 to 0.4 g of each in a total of 3 to 4 g and used to transfect confluent BSR monolayers. Transfected monolayers were overlaid with agarose, and plaques appeared at 3 to 6 days posttransfection (Fig. 6A) . dsRNA from amplified plaques was compared with BTV-1 stock virus on polyacrylamide gels and found to be indistinguishable, confirming that BTV-1 had been recovered (Fig. 6B) . Titration of BTV-1 derived from T7 transcripts exhibited equivalent titers to that of wild-type virus (1 ϫ 10 7 to 3 ϫ 10 7 PFU/ml), demonstrating that BTV-1 derived from the 10 T7 transcripts has no gross replication defects when cultured in BSR cells. To substantiate further that BTV could be derived from T7 transcripts, a mutant of the BTV-1 segment 8 T7 clone was made that contained an introduced silent BglII site, pBTV1S8Bgl. Plaques were recovered from transfections with a complete set of T7 transcripts where the segment 8 BglII marker transcript replaced the wild-type S8 transcript (Fig.  7A) . dsRNA from amplified plaques was found to be indistinguishable from BTV-1 stock virus on polyacrylamide gels (Fig.  7B ). Plaques were amplified by infection of BSR cells, and the S8 segment was amplified by RT-PCR using primers NS2_Bam_R and NS2_Bam_T7_F. Digestion of the RT-PCR product demonstrated that a BglII site had been introduced (Fig. 7C) . The RT-PCR products were sequenced using the BTV1_S8_627R primer confirming the introduction of the marker sequence (Fig.  7D ). These data demonstrate that it is possible to recover BTV from a complete genomic set of T7 transcripts and introduce viable mutations using this system.
DISCUSSION
The two approaches described represent alternative reverse genetics systems for BTV using either a mixture of authentic viral transcripts and T7 transcripts or a complete genomic set of T7 transcripts. These systems extend the discovery that BTV transcripts are infectious when used to transfect permissive cells (1) and demonstrate that in vitro synthesized T7 transcripts with a cap analogue at the 5Ј end can functionally substitute for transcripts synthesized by core particles.
The recovery of progeny virus with genome segments originating from two separate core-derived mRNA preparations established the principle of introducing exogenous transcripts into the genome of BTV by mixing with authentic viral transcripts (Fig. 1B) . The observation that mixing the mRNA prep- arations after transcription was effective in producing reassortants allowed for the possibility of using plasmid-derived transcripts in combination with core-derived mRNAs to introduce targeted mutations into the BTV genome. The introduction of the BTV-10 segment 10 transcript into the genome of BTV-1 was investigated to determine whether the facile introduction of plasmid-derived transcripts into infectious BTV could be achieved. A 5:1 molar ratio of T7 transcript to the corresponding core-derived mRNA was found to give a high frequency of reassortant plaques while maintaining the total recovery of plaques at a practical number. The observation that higher ratios of T7 transcript reduced the total plaque count may be due to negative effects on virus replication caused by overexpression of one gene in comparison to other genes. Alternatively, the reduced recovery may derive from the fact that only a portion of T7 transcripts generated in the presence of a cap analogue have the cap analogue incorporated at the 5Ј end. Additionally, the uncapped transcripts have a 5Ј triphosphate moiety that is known to be a pathogenassociated molecular pattern recognized by RIG-I that may lead to the induction of antiviral responses (3, 6, 20, 21) . This model system showed that using an excess of the T7 transcript generated reassortant plaques at a frequency that made the screening of individual plaques practical (15 to 80%). The variation in this efficiency may reflect variation in the quality or the degree of capping of different T7 transcript preparations. The initial screening of plaques by the rate of migration of the segment 10 dsRNA on polyacrylamide gels (Fig. 2) was confirmed by sequencing of the RT-PCR product (Fig. 2) . The high efficiency of reassortment between the T7 transcript and authentic viral transcripts meant that a selectable marker approach was not required. The introduction of the HaeII site marker mutation into segment 10 of BTV confirmed that reassortants were derived from the in vitro synthesized segment 10 T7 transcript (Fig. 3) . The HaeII-containing segment 10 was recovered with a similar efficiency to wild-type BTV-10 segment 10. Neither segment 10 reassortant virus demonstrated any gross replication deficiencies compared to wild-type BTV-1 (data not shown). This shows that genome segment 10 from BTV-10 is functionally compatible with a background of BTV-1 genome segments both at the levels of RNA packaging and replication and NS3/NS3A protein function. The simultaneous reassortment of two T7 transcripts into the BTV genome to replace the antigenically important outer capsid proteins of BTV-1 with those from BTV-10 cDNA clones was shown to be possible using an excess of both T7 transcripts (Fig. 4) . Progeny plaques containing the BTV-10 segments 2 and 5 were recovered at a 20 to 80% frequency, but no reassortants were isolated containing only segment 2 or segment 5 from BTV-10. This demonstrates that together segments 2 and 5 of BTV-10 can functionally substitute for the corresponding BTV-1 genome segments and suggests that there is incompatibility between segment 2 and segment 5 from these two serotypes at some level. The encoded proteins, VP2 and VP5, are highly variable due their exposure to immune selective pressure on the surface of the virus particle. Our favored explanation is that the VP2 and VP5 proteins have coevolved and that the three dimensional structure of VP2 from one serotype is not necessarily compatible with the VP5 from another serotype. This is consistent with the previously reported incompatibility of the VP2 and VP5 proteins from some serotype combinations observed in the generation of BTV virus-like particles (11, 28) . Incompatibility of segment 2 and segment 5 in some serotype combinations at an RNA packaging level is another possibility. The simultaneous introduction of both outer capsid proteins from another serotype allows the possibility of producing vaccine strains to different serotypes based on a consistent genetic background. The high amino acid sequence divergence between the VP2 proteins of BTV-1 and BTV-10 (40% amino acid identity) suggests that the assembly of varied VP2-VP5 pairs onto the conserved core of the BTV virion will be possible.
The recovery of BTV-1 from a complete set of T7 transcripts was investigated to determine whether virus with a fully defined genome could be recovered from cDNA clones. Transfection of BSR monolayers with the 10 T7 transcripts was found to lead to the production of plaques (Fig. 6) . The recovery of a BglII marker mutation into the S8 segment confirmed that the virus recovered was derived from the T7 transcripts used in the transfections (Fig. 7) . The recovery of infectious BTV from T7 transcripts alone demonstrates that T7 transcripts synthesized in the presence of cap analogue are functionally equivalent to authentic viral transcripts at all stages of the replication cycle. The T7 transcripts must be translated and selected during genome packaging and must act as templates for negative-strand synthesis if virions are to be generated. Furthermore, after negative-strand synthesis, the resulting dsRNA genome segment must be competent for transcription in the next round of infection. The recovery of BTV from T7 transcripts leads to the recovery of ϳ100-fold fewer plaques than when an equivalent quantity of core-derived viral transcripts is used. The lower efficiency may derive from the fact that only a portion of T7 transcripts generated in the presence of a cap analogue have the cap analogue incorporated at the 5Ј end. In addition to being poorly translated, the uncapped transcripts may be defective during RNA packaging, negative-strand synthesis, or transcription in the next round of infection. Additionally the induction of antiviral responses to the 5Ј triphosphate via RIG-I may influence the recovery of virus (3, 6, 20, 21) . Alternatively, the technical issues associated with generating 10 ssRNA molecules with the conserved terminal sequences intact may contribute to the lower recovery observed with T7 transcripts. The presence of transcripts shorter than full-length that derive from incomplete transcription or the degradation of full-length transcripts is a minor component in every T7 transcript preparation (Fig.  5) . These transcripts may be expected to reduce the efficiency of recovery of infectious virus through their incorporation into assembling virions.
The recovery of BTV entirely from plasmid-derived transcripts allows the generation of BTV mutants with a consistent genetic background. This approach will be useful in the recovery mutants, which are expected to have a slow replication phenotype, as the screening of plaques for the desired mutant among wild-type plaques is not required. In such cases there would be no background of faster-replicating virus, which may hamper the recovery of the slower-replicating mutants. This approach could also be used to recover primary/low-passage isolates of BTV, avoiding gradual alteration of these strains to cell culture conditions. The recovery of reassortants containing one plasmid-derived genome segment requires the construction of a single clone or PCR product and is applicable to any genome segment. This single-construct approach can be used to investigate individual viral genes without the need to construct a full set of 10 clones. As Reoviridae members have a common replication strategy, both the reassortment and T7-only reverse genetics approaches may be applicable to a wide range of viruses which lack a reverse genetics system. The use of in vitro synthesized T7 transcripts in both approaches obviates the requirement to supply T7 RNA polymerase by infection with a recombinant poxvirus, which may interfere with the replication of the virus being recovered.
Alternative reverse genetics strategies have been used successfully for other genera in the Reoviridae (9, 10, 26) . The first reverse genetics system was a helper virus system for the mammalian orthoreoviruses (26) . This approach combined reovirus infection of permissive cells and transfection with viral dsRNA, viral mRNA, a T7 transcript, and in vitro translated viral mRNA. Another helper virus approach has allowed the replacement of a rotavirus outer capsid protein with the corresponding protein from another serotype (10) . The expression of the introduced genome segment was driven in vivo by the recombinant T7 vaccinia virus system, and selective pressure against the equivalent helper virus protein was provided by the use of antibody selection. Most recently mammalian orthoreovirus has been recovered using a plasmid-based system similar to the T7-driven systems first used with negative-strand viruses (9) . In this case expression of all 10 genome segments was driven in vivo by the recombinant T7 vaccinia virus system. All the successful reverse genetics strategies for members of the family have several notable features in common. (i) The genome segments derived from cDNA clones are provided as message sense transcripts in the transfected cell. (ii) The cDNA-derived transcripts used have the same 5Ј end and 3Ј end sequences as the corresponding viral transcript. The 5Ј ends are generated through the use of a T7 promoter with the appropriate sequence, and the 3Ј ends are generated through the use of the hepatitis delta ribozyme in vivo or a restriction enzyme site in vitro. All genome segments in Reoviridae members have short conserved sequences at their extreme 5Ј and 3Ј ends the functions of which are still being elucidated. (iii) Like the authentic viral transcripts, the cDNA-derived transcripts are capped, either in vitro with a cap analogue or in vivo through the cross-capping activity associated with the vaccinia T7 RNA polymerase recombinant (4). To achieve infectious virus recovery, gene expression must be sufficient to allow the assembly of progeny core particles, which themselves are transcriptionally active and lead to an amplification of gene expression. A high level of gene expression is needed to assemble these incomplete virions, and without the presence of the cap structure at the 5Ј end of the cDNA-derived transcripts, their stability and level of translation would be greatly reduced (17) .
Reverse genetics, as with other viruses, can contribute to the understanding of BTV in several research areas. The ability to recover specific mutations into the genome of BTV using either system provides not only a novel tool for the molecular dissection of BTV and related orbiviruses but also the opportunity to develop specifically attenuated vaccines to these viruses. The investigation of BTV protein function to date has mainly been based on recombinant protein expression. The ability to introduce specific mutations into the genes of BTV will further our understanding of the functions of the viral proteins in replicating virus and allow the corroboration of functions already assigned. The cis-acting RNA sequences that control the replication, packaging, and expression of Orbivirus genomes remain unmapped and are poorly understood. Reverse genetics allows mapping of these regulatory sequences and can assist in the investigation of how they act. The replacement of outer capsid proteins can be used to generate vaccine strains to different serotypes based on a common genetic background. Moreover, it will be possible to identify determinants of pathogenicity of BTV and related orbiviruses and design multiply attenuated vaccine strains.
